In recent days, researchers have released the results of a study towards prostate cancer. Compared with other treatments for prostate cancer, degarelix is able to play a greater role in reducing the risk of cardiovascular events.
Bertrand Tombal from the University of Leuven, Belgium in French zones and Kurt Miller from the Benjamin Franklin Medical Center in Berlin, Germany have conducted a detailed study based on this issue. They said that the research data has shown degarelix can significantly reduce the risk of cardiovascular events when compared with conventional prescriptions which can luteinize hormone-releasing hormone agonist. Whereas, the former one often leads to decreased testosterone levels in male patients.
Compared with other patients in different periods, men who have cardiovascular disease can benefit more. The results have indicated that receiving degarelix treatment can be better in prostate cancer patients with advanced condition, and the risk for heart disease, stroke and other cardiovascular diseases as well as death risk has been reduced by more than 50%. The data derived from patients with prostate cancer in different countries could count to 2328 meta-analysis cases.
The study also found that patients receiving degarelix treatment has significantly increased overall survival while compared with the acceptance of luteinizing hormone-releasing hormone agonists. In addition, the symptom of prostate cancer has been improved to a certain degree, and the probability of fractures, bad kidneys and urinary system have realized reduction reaction. Studies also show degarelix may help other disease treatments as well.
In brief, much of human biology is still speculative, and its interaction with environment is intricate. Thus medical science has enormous potential for useful research. At the same time it has its own risks as well!
Edited by Chloe Mica, 12 May 2016 - 12:38 AM.